Safe use of nivolumab in a patient with renal cell carcinoma and hepatitis B.

Immunotherapy with checkpoint inhibitors gains a major role in bladder cancer. Because of the treatment’s immune modulatory effects, patients may develop hepatitis. Hepatitis B was an exclusion criterion in clinical trials that investigated nivolumab. Therefore, its effects and risk of hepatitis B reactivation in nivolumab are not clinically investigated in renal cell carcinoma patients with […]

Prognostic value of the albumin-to-alkaline phosphatase ratio on urologic outcomes in patients with non-metastatic renal cell carcinoma following curative nephrectomy.

Background: Few studies focused on the relationship between the albumin-to-alkaline phosphatase ratio (AAPR) and the urologic outcomes in patients with non-metastatic renal cell carcinoma (RCC) following curative surgery. The aim of this study was to evaluate the prognostic value of preoperative AAPR in non-metastatic RCC patients. Methods: The prognostic value of AAPR was evaluated in […]

Comparison of gemcitabine and anthracycline antibiotics in prevention of superficial bladder cancer recurrence.

Because of the failure, shortage and related toxicities of Bacillus Calmette-Guérin (BCG), the other intravesical chemotherapy drugs are also widely used in clinical application. Gemcitabine and anthracycline antibiotics (epirubicin and pirarubicin) are widely used as first-line or salvage therapy, but which drug is better is less discussed. A total of 124 primary NMIBC patients administered […]

The role and effect of FDG-PET/CT on patient management and restaging of bladder carcinoma.

To compare the diagnostic role of Florine-18 2-fluoro-2-deoxy-D-glucose-Positron emission tomography/computed tomography (FDG-PET/CT) in the restaging of bladder cancer with other radiological methods and to determine its effect on the treatment management of patients with bladder cancer. A total of 83 patients who showed suspicious lesions with radiologic methods and FDG-PET/CT images were enrolled in the […]

WCE 2019: Quality of Life in Stone Formers

Abu Dhabi, United Arab Emirates (UroToday.com) This session was divided into 3 parts discussing quality of life in stone-forming patients. Dr. Kristina Penniston gave an overview of different instruments developed to measure and assess quality of life. Dr. Charles Scales described the use of these instruments in patients with ureteral stents. Dr. Justin Ziemba finished […]

WCE 2019: Breaking Stones: What is Best for PCNL?

Abu Dhabi, United Arab Emirates (UAE) (UroToday.com) Dr. Amy Krambeck, Professor of Urology at the University of Indiana, presented on lithotripsy and which modality is best for breaking stones during percutaneous nephrolithotomy (PCNL). The clearance of large renal stones during PCNL requires an energy source to break the stone. Options that are available include pneumatic, […]

ACS 2019: A Pilot Study of De-Implementation of Empiric Vancomycin Use in Surgical Inpatients

San Francisco, California (UroToday.com) Leah Chisholm, Vanderbilt University School of Medicine, Nashville, TN discussed how surgical inpatients suspected of infection are frequently treated empirically with the antibiotic vancomycin to cover for potential Methicillin-resistant Staphylococcus aureus (MRSA) and Enterococcus faecium (E. faecium) infection. Non-soft tissue MRSA and EF infections are relatively rare in surgical populations and vancomycin […]

Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-Analysis – Beyond the Abstract

Multiparametric MRI (mpMRI) has significantly impacted on the diagnostic pathway of prostate cancer.1 Recent NICE (The National Institute for Health and Care Excellence)2 and EAU (European Association of Urology)3 guidelines now advocate pre-biopsy mpMRI in the assessment and diagnosis of suspected prostate cancer irrespective of previous biopsy status. Utilising a collaborative research model through the BURST […]

X